Stämm

Inside a lab where the bioreactor doesn't hum.

In a quiet room in Monthey, Switzerland, a small box is producing antibodies. It does not have an impeller. It does not bubble. It is roughly the size of a shoebox and it was, in part, printed. A team in San Francisco watches its sensors light up on a dashboard. A team in Buenos Aires has just calibrated its cell line. The medicine inside the cartridge was not produced by a 12-story plant outside Boston. That is the point.

This is Stämm, a company that has spent more than a decade arguing - politely, with a great deal of math - that the way the world makes biologic drugs is overdue for an upgrade. Their wager is straightforward, if not exactly modest: the giant, centralized stainless-steel bioreactor, that workhorse of modern pharma, has run out of room to improve. So Stämm has built a smaller one. Faster. Smarter. Closer to the patient.

Biomanufacturing is the bottleneck nobody talks about.

The discovery side of biotech gets the headlines. The manufacturing side gets the budgets. A modern biologics plant can cost north of half a billion dollars to build, take four years to validate, and remain stubbornly inflexible once it opens. Cell therapies, which need to be manufactured one patient at a time, fit awkwardly into this world - which is to say, they don't fit at all.

The traditional answer is the stirred-tank bioreactor: a vast metal cylinder full of cells, sugar, oxygen and a slowly turning impeller. It works. It also bruises the cells with shear stress, wastes media at scale, and demands an army of operators in moon suits. For monoclonal antibodies it is acceptable. For the next wave of personalized medicines, it is a mismatch.

Stämm looked at this and saw a software problem dressed as a hardware problem. Or, depending on how you squint, a hardware problem dressed as a software problem.

Two cousins, a homebrew kit, and a useful kind of stubbornness.

The company traces its origin, as all good biology stories should, to beer. In 2013, cousins Yuyo Llamazares Vegh and Federico D'Alvia Vegh started brewing in Buenos Aires. They quickly noticed that the equipment used to produce a hobbyist lager was not so different from the equipment used to produce a clinical-grade antibody - just larger, and considerably more expensive. The inefficiencies they saw at small scale repeated at industrial scale. They decided to do something about it.

The bet had three parts. First: that the geometry of the bioreactor could be reinvented if you stopped using a metal vessel and started 3D-printing the fluid pathways instead. Second: that production should be continuous rather than batch-based - a steady drip, not a slow boil. Third: that an AI model trained on multi-omics data could orchestrate the whole thing in real time, with minimal human intervention.

None of these ideas were original on their own. Combining all three into a working, sterile, regulated, commercial product was - and remains - the trick.

The bubble-free, 3D-printed, plug-and-play bioprocessor.

In March 2026, Stämm formally launched what it had been quietly building: the High-Throughput Bioprocessor, or HTB. At its core sits the Bubble-Free Bioreactor, a single-use, 3D-printed consumable that abolishes the impeller entirely. Oxygen and nutrients are delivered through microfluidic channels printed directly into the cartridge. The cells, no longer beaten up by a spinning blade, are reportedly much happier - and considerably more productive.

It is, in essence, three companies stacked on top of one another. There's a hardware company building the printer-cartridges and the benchtop hardware. There's a wet-lab company doing clone selection and cell line development for clients. And there's a software company - the Bio AI platform - that uses generative models to simulate cellular behavior and tune the process while it runs.

The HTB ships today as a Research Use Only product, which is the polite biotech way of saying "you can buy it, but we're not yet approved to make your finished drug in it." That part - the GMP-grade, regulator-blessed version - is what the next several years are for.

What's actually in the box

• Hardware: a benchtop, automated bioprocessing unit with sensors, pumps and cloud control.
• Consumable: a 3D-printed Bubble-Free Bioreactor cartridge, customizable per application.
• Software: the Bio AI platform - multi-omics analysis, cell-state simulation, perturbation analysis.
• Service: end-to-end cell line development, from clone selection to stable banks.

Numbers, partners, and a Harvard case study.

Biotech is allergic to bold claims that lack receipts. Stämm has, in its short and slightly improbable life, accumulated a few. The most cited is a 30x increase in antibody productivity over conventional stirred-tank bioreactors in early pilots. That figure is - in fairness - a pilot result, not a universal guarantee. But it is large enough to be interesting, and consistent enough to be repeated.

The institutional validation is similarly cumulative. Draper Associates wrote the first big check. SOSV's IndieBio fed the company through an SF biotech bootcamp. Harvard Business School wrote not one but two case studies on the company's strategy of decentralized biomanufacturing - a turn of events that academics would call "instructive" and founders would call "free marketing." Industry partnerships across Argentina, Switzerland and Israel are now being extended toward India, the US, and China.

Decentralize the drug supply, then teach it to think.

Strip away the hardware and the renderings, and Stämm's mission resolves into something that sounds almost civic. The company would like the production of biologics and cell therapies to look less like the petrochemical industry and more like, say, the coffee industry: distributed, local, responsive, instrumented. Drugs made closer to the patient. Capacity that can be added in weeks instead of years. A supply chain that doesn't snap when a single plant in Puerto Rico catches a hurricane.

The longer-term ambition is even more interesting. If every Stämm bioprocessor is connected, sensing, and streaming data, the company sits on a fleet of biological factories that learn from one another. Train the Bio AI on that data and you get something the industry has chased for decades: a process that genuinely improves with use, rather than freezing the moment a regulator signs the file.

It is a long bet. The closer the technology gets to clinical use, the more friction it accumulates - regulators, validation, scale-up, the conservative gravity of pharma. Stämm is well aware. The founders have, at various points, described the path to GMP approval as "the actual hard part." This is a refreshingly grown-up thing for a deep-tech founder to say.

Small machines, big consequences.

The next decade of medicine is unlikely to be defined by one more billion-dollar plant in New Jersey. It is more likely to be defined by personalized therapies, regional manufacturing, and software-controlled production lines that can pivot overnight from antibody A to antibody B. If that future arrives, the companies that ship the picks-and-shovels - the small, smart, instrumented bioreactors - will quietly own a very large piece of it.

Stämm is not the only group chasing this idea. It is, however, one of very few that has actually shipped a working consumable, opened operations on three continents, and convinced both an Argentine grid-tech VC and an American deep-tech accelerator that the numbers will close. That is not a guarantee of victory. It is, in a sector that mostly traffics in slide decks, a meaningful head start.

Back in the quiet room in Monthey, the small box on the bench is still producing antibodies. It does not hum. It does not bubble. It does not need a 12-story building around it. If Stämm is right about even half of what it believes, that small box is what the future of medicine looks like - and the future of medicine will fit, more or less, on a shelf.